Skip to main content

Peer Review reports

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Original Submission
12 Apr 2019 Submitted Original manuscript
28 Jun 2019 Author responded Author comments - Javier Puente
27 Apr 2019 Reviewed Reviewer Report - Masaki Shiota
7 May 2019 Reviewed Reviewer Report - Hyonok Yoon
Resubmission - Version 2
28 Jun 2019 Submitted Manuscript version 2
21 Jul 2019 Author responded Author comments - Javier Puente
2 Jul 2019 Reviewed Reviewer Report - Masaki Shiota
4 Jul 2019 Reviewed Reviewer Report - Hyonok Yoon
Resubmission - Version 3
21 Jul 2019 Submitted Manuscript version 3
Publishing
23 Jul 2019 Editorially accepted
5 Aug 2019 Article published 10.1186/s12885-019-5974-9

You can find further information about peer review here.

Back to article page